Skip to content
DraconiticResearch
Search Sources API
197,768 studies31 sourcesUpdated 36 min ago
PreprintAll rights reservedmedRxiv

Immune Profiling after treatment with an Anti-CD19 Chimeric Antigen Receptor T Cell Therapy in Treatment-Refractory Progressive Multiple Sclerosis

  • S. Gupta
  • M. R. Seshadri
  • R. Dandekar
  • L. Mueller-Jensen
  • K. McCutcheon
  • L. A. Scarffe
  • S. Vanasupa
  • M. Sunahara
  • F. Hayashi
  • C. Caspar
  • R. Lincoln
  • N. Okinishi
13 more authors
  • N. Thomas
  • S. Shenoy
  • S. Zylberman
  • C. Fouassier
  • E. Hassan
  • S. Klauer
  • J. Wilmoth
  • J. J. Sabatino
  • A. Bodansky
  • A. Abdelhak
  • S. L. Hauser
  • M. R. Wilson
  • B. A. C. Cree1
  1. 1University of California, San Fransisco
Read full textPDFDOICite

Related

  1. A Case of Treatment‐Refractory Tumefactive Multiple Sclerosis Mimicking Brain Abscess
    Pooja Patel, Henrik Ehrhardt, Daniel Augh +2
    Case Reports in Neurological MedicinePeer-reviewedCC BY 4.0Full textGeneral medicinePMC
  2. P044 Mönckeberg’s medial sclerosis as a mimic for giant cell arteritis refractory to treatment
    Richard Weir, Elizabeth Coulson
    Rheumatology advances in practicePeer-reviewedCC BYFull textGeneral medicineEurope PMCPMC
  3. Transcriptome Analysis Identifies a Myeloid-Like Signature in Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Patients With Poor Response to CD19 Chimeric Antigen Receptor T Cell Therapy.
    Shisen Wang, Wenbing Liu, Ying Wang +10
    Cancer medicinePeer-reviewedCC BY-NC-NDFull textEpidemiology & public healthEurope PMC
  4. Chronic lesion expansion persists in secondary progressive multiple sclerosis and is associated with neurodegeneration
    S. Klistorner, M. Barnett, A. Klistorner
    medRxivPreprintAll rights reservedFull textNeurologymedRxiv
  5. Baseline Spleen Volume is Independently Associated With Survival After CD19-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma.
    Lucas Brehm, Philipp Schindler, Christian Römer +11
    Hematological oncologyPeer-reviewedCC BYFull textOncologyEurope PMCPMC

Cite

BibTeXRIS
BibTeX
@misc{gupta2026immune,
  title = {{Immune Profiling after treatment with an Anti-CD19 Chimeric Antigen Receptor T Cell Therapy in Treatment-Refractory Progressive Multiple Sclerosis}},
  author = {S. Gupta and M. R. Seshadri and R. Dandekar and L. Mueller-Jensen and K. McCutcheon and L. A. Scarffe and S. Vanasupa and M. Sunahara and F. Hayashi and C. Caspar and R. Lincoln and N. Okinishi and N. Thomas and S. Shenoy and S. Zylberman and C. Fouassier and E. Hassan and S. Klauer and J. Wilmoth and J. J. Sabatino and A. Bodansky and A. Abdelhak and S. L. Hauser and M. R. Wilson and B. A. C. Cree},
  howpublished = {medRxiv},
  year = {2026},
  month = sep,
  doi = {10.64898/2026.09.11.26361992},
  url = {https://www.medrxiv.org/content/10.64898/2026.09.11.26361992v1},
}
RIS
TY  - UNPB
TI  - Immune Profiling after treatment with an Anti-CD19 Chimeric Antigen Receptor T Cell Therapy in Treatment-Refractory Progressive Multiple Sclerosis
AU  - S. Gupta
AU  - M. R. Seshadri
AU  - R. Dandekar
AU  - L. Mueller-Jensen
AU  - K. McCutcheon
AU  - L. A. Scarffe
AU  - S. Vanasupa
AU  - M. Sunahara
AU  - F. Hayashi
AU  - C. Caspar
AU  - R. Lincoln
AU  - N. Okinishi
AU  - N. Thomas
AU  - S. Shenoy
AU  - S. Zylberman
AU  - C. Fouassier
AU  - E. Hassan
AU  - S. Klauer
AU  - J. Wilmoth
AU  - J. J. Sabatino
AU  - A. Bodansky
AU  - A. Abdelhak
AU  - S. L. Hauser
AU  - M. R. Wilson
AU  - B. A. C. Cree
PY  - 2026
DA  - 2026/09/11
PB  - medRxiv
DO  - 10.64898/2026.09.11.26361992
UR  - https://www.medrxiv.org/content/10.64898/2026.09.11.26361992v1
ER  -